UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)

被引：0
|
作者：
Gullick, G. [1 ]
Owen, C. [2 ]
Cook, S. [3 ]
Helbrow, J. [4 ]
Squires, R. [1 ]
Reed, H. M. [1 ]
Park, S.
Weir, E. [5 ]
Aquilina, F. [5 ]
Webber, N. [6 ]
Nye, E. [6 ]
Atkinson, C. [3 ]
Blair, C. [1 ]
Halstead, A. [1 ]
Daniels, E. [4 ]
Alves, A. [1 ]
Chew, S. [5 ]
Thomas, W. [4 ]
Spensley, S. [3 ]
Robinson, T. [2 ]
机构：
[1] Bristol Canc Inst, Med Oncol Dept, Bristol, England
[2] Univ Bristol, Fac Hlth Sci, Bristol Med Sch, Bristol, England
[3] Taunton & Somerset NHS Fdn Trust, Oncol Dept, Musgrove Pk Hosp, Taunton, England
[4] Gloucestershire Hosp NHS Fdn Trust, Oncol Dept, Gloucestershire Oncol Ctr, Cheltenham Gen Hosp, Cheltenham, England
[5] NHS Royal Devon Univ Healthcare, Oncol Dept, Royal Devon & Exeter Hosp Wonford, Exeter, England
[6] Royal United Hosp Bath NHS Fdn trust, Oncol Dept, Bath, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
422P
引用
收藏
页码：S360 / S360
页数：1
相关论文
共 50 条
  • [1] The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)
    Eiger, Daniel
    Wagner, Marcio
    Ponde, Noam F.
    Nogueira, Melanie S.
    Buisseret, Laurence
    de Azambuja, Evandro
    ACTA ONCOLOGICA, 2020, 59 (06) : 723 - 725
  • [2] Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
    Tavara, B. I.
    Garrido, M. L.
    Lopez, L.
    Lopez Flores, M.
    Castanon, C.
    Abella Alvarez, S.
    Medina Valdivieso, S.
    Rodriguez Sanchez, A.
    Garcia Palomo-Perez, A.
    Lopez, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S361
  • [3] Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
    Foffano, L.
    Cucciniello, L.
    Nicolo, E.
    Migliaccio, I.
    Noto, C.
    Reduzzi, C.
    Malorni, L.
    Cristofanilli, M.
    Gerratana, L.
    Puglisi, F.
    Pitigliani, Sandro
    BREAST, 2025, 79
  • [4] Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
    von Arx, C.
    Calabrese, A.
    Martinelli, C.
    Di Lauro, V.
    Grimaldi, V.
    Pensabene, M.
    Caputo, R.
    Cerillo, I.
    Cianniello, D.
    Buono, G.
    Verrazzo, A.
    Pacilio, C.
    Di Rella, F.
    Nuzzo, F.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S370 - S370
  • [5] Whole exome sequencing (WES) in hormone-receptor positive (HR plus ) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
    Wander, Seth Andrew
    Cohen, Ofir
    Johnson, Gabriela N.
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Nayar, Utthara
    Helvie, Karla
    Marini, Lori
    Freeman, Samuel
    Getz, Gad
    Garraway, Levi A.
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR plus MBC) with ESR1 mutations and fusions
    Brett, Jamie O.
    Weipert, Caroline M.
    Ritterhouse, Lauren L.
    Zhang, Nicole
    Yu, Junhua
    Ryan, Lianne Y.
    Spring, Laura M.
    Rivera, Miguel N.
    Lennerz, Jochen K.
    Dias-Santagata, Dora
    Ellisen, Leif W.
    Bardia, Aditya
    Wander, Seth A.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] RETRACTED: Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC). (Retracted Article)
    Raimondi, Lucrezia
    Di Benedetto, Laura
    Naso, Giuseppe
    Raimondi, Filippo Maria
    Di Rocco, Arianna
    Giaconi, Laura
    Lazzeroni, Rachele
    Spinelli, Gian Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Mai, Nicholas
    dos Anjos, Carlos H.
    Razavi, Pedram
    Safonov, Anton
    Patil, Sujata
    Chen, Yuan
    Drago, Joshua Z.
    Modi, Shanu
    Bromberg, Jacqueline F.
    Dang, Chau T.
    Liu, Dazhi
    Norton, Larry
    Robson, Mark
    Chandarlapaty, Sarat
    Jhaveri, Komal
    NPJ BREAST CANCER, 2024, 10 (01)
  • [9] Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
    Thill, Marc
    Schmidt, Marcus
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [10] Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
    Graf, F.
    Mosch, B.
    Koehler, L.
    Bergmann, R.
    Wuest, F.
    Pietzsch, J.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2010, 10 (06) : 527 - 539
12345